Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 ...

SHANGHAI (Reuters) -The Beijing-based American Chamber of Commerce said on Friday that companies in the pharmaceutical sector ...

Merck KGaA is nearing a deal to acquire SpringWorks Therapeutics Inc., people familiar with the matter said. An announcement ...

Merck’s first-quarter net income increased as sales of its Keytruda cancer drug rose, but the Big Pharma company cut its 2025 ...

For 2025, Merck said it still expects sales of $64.1 billion to $65.6 billion, but it lowered its adjusted earnings per share ...

Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 ...

A biotech company is suing to block Merck & Co. from launching an easier-to-use version of its blockbuster cancer treatment ...

Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...

Merck KGaA has confirmed that it is in late-stage discussions with SpringWorks, valuing the deal at a price of around $47 per ...

Merck (MRK) stock rises as Summit Therapeutics (SMMT) posts latest survival data for lung cancer therapy ivonescimab ...

Merck projects $200 million in tariff costs, boosts U.S. manufacturing plans, and continues M&A efforts amid external pressures and shifting market dynamics.

So far, SpringWorks – which was spun out of Pfizer in 2017 and has recently received FDA approval for a second therapy for a ...